195 results on '"Pater, Joseph L"'
Search Results
2. Validating Restricted Mean Survival Time Estimates From Reconstructed Kaplan-Meier Data Against Original Trial Individual Patient Data From Trials Conducted by the Canadian Cancer Trials Group
3. Methodological Issues in Antiemetic Studies
4. Application of Value Frameworks to the Design of Clinical Trials: The Canadian Cancer Trials Group Experience
5. A Canadian Prospective Study of Linkage of Randomized Clinical Trial to Cancer and Mortality Registry Data
6. Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial
7. The importance of temporal effects in evaluating the prognostic impact of joint ERPR expression in premenopausal women with node-positive breast cancer
8. Drug-induced Thrombotic Microangiopathy with Concurrent Proteasome Inhibitor Use in the Treatment of Multiple Myeloma: A Case Series and Review of the Literature
9. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer
10. Priority-setting decisions for new cancer drugs: a qualitative case study
11. Identifying Breast Cancer Patients Most Likely to Benefit From Aromatase Inhibitor Therapy After Adjuvant Tamoxifen
12. Quality of Life in a Randomized Control Trial? Comments Concerning MA 17.
13. Re: Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17
14. Assessment of Quality of Life in MA.17: A Randomized, Placebo-Controlled Trial of Letrozole After 5 Years of Tamoxifen in Postmenopausal Women
15. Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17
16. Treatment of locally advanced breast cancer
17. Application of Value Frameworks to the Design of Clinical Trials: The Canadian Cancer Trials Group Experience.
18. Letrozole in Breast Cancer
19. Ovarian Ablation as Adjuvant Therapy for Premenopausal Women With Breast Cancer—Another Step Forward
20. Enrollment of Older Patients in Cancer Treatment Trials in Canada: Why is Age a Barrier?
21. Optimal Chemotherapy for Women With Breast Cancer: The Plot Thickens
22. Activity of intravenous menogaril in patients with previously untreated metastatic breast cancer: A National Cancer Institute of Canada Clinical Trials Group study
23. Ethics and industry-sponsored research
24. Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil
25. Enrollment of elderly patients in cancer treatment trials in Canada: Why is age a barrier?
26. Pilot study of the ability to probabilistically link clinical trial patients to administrative data and determine long-term outcomes
27. Randomized phase III trial of single versus fractionated thoracic radiation in the palliation of patients with lung cancer (NCIC CTG SC.15)
28. Antiemetic Properties of Granisetron
29. Polychemotherapy in advanced non-small-cell lung cancer
30. Assessing the reliability of two toxicity scales: implications for interpreting toxicity data
31. A critical appraisal of ticlopidine, a new antiplatelet agent: effectiveness and clinical indications for prophylaxis of atherosclerotic events
32. # 1635/Maintaining Compliance in Quality of Life Data Completion in Clinical Trials: The National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) Experience
33. Prospective linkage of clinical trial and administrative databases: Acceptability to patients and research ethics boards.
34. A value framework analysis of the Canadian Cancer Trials Group.
35. The Timing of Baseline Quality of Life in Clinical Trials
36. Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17
37. Pilot study of the ability to probabilistically link clinical trial patients to administrative data and determine long-term outcomes.
38. Priority-setting decisions for new cancer drugs
39. The economic impact of the transition from branded to generic oncology drugs.
40. Patient preferences for research access to administrative data in Ontario.
41. Correlation of single arm versus randomised phase 2 oncology trial characteristics with phase 3 outcome
42. Bilateral Massive Adrenal Hemorrhage
43. Clinical predictors of failure of granulocyte colony stimulating factor (G-CSF) prophylaxis in patients with breast cancer treated with dose dense epirubicin (E), cyclophosphomide (C) + paclitaxel (T) Adjuvant chemotherapy: Subgroup analysis of the NCIC CTG MA.21 study (NCT00014222).
44. Abstract P3-09-02: Association between definitive surgery and times to administration of adjuvant chemotherapy and outcomes in early breast cancer: Analysis of adjuvant studies conducted by NCIC Clinical Trials Group (NCIC CTG)
45. Accrual of adolescents and young adults with cancer to eligible clinical trials: A report from the NCIC Clinical Trials Group (NCIC-CTG).
46. Correlation between phase 2 clinical trial design and subsequent phase 3 outcome.
47. Improving cancer clinical trial accrual in Ontario, Canada: The clinical trials infrastructure fund (CTIF) experience.
48. The association of treatment-emergent proteinuria (TEP) with baseline/treatment variables in patients (pts) treated with antiangiogenic tyrosine kinase inhibitors (AA-TKIs): A pooled analysis of NCIC Clinical Trial Group (NCIC CTG) trials.
49. Estimation of drug cost avoidance (DCA) and pathology cost avoidance (PCA) through participation in NCIC clinical trials group (NCIC-CTG) phase III clinical trials in Canada.
50. Quality of Life in MAP.3 (Mammary Prevention 3): A Randomized, Placebo-Controlled Trial Evaluating Exemestane for Prevention of Breast Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.